이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

HCV 관련 간 섬유증의 스펙트럼 전반에 걸친 미생물 전좌와 관련된 메커니즘 해독

HCV 관련 간 섬유증의 스펙트럼에 걸친 미생물 전좌와 관련된 메커니즘을 해독하기 위한 다학제적 접근법

Background:

- Hepatitis C infection (HCV) is a leading cause of liver disease. Normal bacteria from the intestines may spread to the liver and blood during liver disease. This is called bacterial translocation (BT). Researchers think BT may cause liver disease to worsen.

Objectives:

- To study the mechanisms involved in BT in early and advanced liver disease. To find out whether BT causes liver disease to worsen.

Eligibility:

- People over age 18 with HCV and clinically stable liver disease.

Design:

  • Participants will be screened with medical history and physical exam. They will have blood tests and imaging studies.
  • Participants will have 2 outpatient visits and a 3-day stay at the clinic.
  • At visit 1, participants will have urine and blood tests. They will have a magnetic resonance imaging (MRI) scan. A solution will be injected into a vein. The MRI scanner is a metal cylinder surrounded by a magnetic field. The participant will lie on a table that slides in and out of the cylinder.
  • At visit 2, a substance will be injected into a vein and swallowed. Participants will then have blood drawn 5 times over 90 minutes.
  • During the inpatient stay, serial blood tests will be drawn.
  • Participants will give 2 stool samples and have another MRI.
  • A needle will be inserted through the chest wall into a vein inside the liver, guided by ultrasound. The blood pressure inside this vein will be measured and blood will be drawn from it. About 1 inch of liver tissue will be removed.
  • A study investigator will call participants to discuss all test results.

연구 개요

상태

완전한

정황

상세 설명

Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the systemic circulation is considered a pivotal mechanism contributing to the development of life-threatening complications in end stage cirrhosis. Recent evidence suggests that the liver and systemic circulation may be exposed to gut derived microbial products at earlier stages of liver disease. This early exposure may trigger hepatic inflammation, modify immune host response and accelerate hepatic fibrogenesis; which, in turn, impairs portal inflow, alters the portal circulation, and leads to development of portal hypertension. The mechanisms resulting in systemic exposure to gut derived microbial products, and the subsequent host response to BT has not been studied in patients with early liver disease nor fully compensated cirrhosis.

We therefore intend to enroll 30 chronic HCV patients with either cirrhosis (20) or minimal liver fibrosis (10). Study participants will undergo extensive evaluation with portal vein sampling and pressure measurements, dual cholate clearances, liver biopsy, serologic, immunologic, fecal microbiome and imaging studies. This will be followed by an optional second percutaneous liver biopsy and portal vein sampling 9-15 months after HCV treatment. The treatment protocol is a separate independent protocol, 15-DK- 0143 utilizing Sofosbuvir and GS-5816. The goals of our study are to characterize the extent of BT in early stages of cirrhotic and non-cirrhotic liver disease, explore the mechanisms contributing to its occurrence and identify potential serological, immunological and hemodynamic biomarkers associated with chronic infection. This, in turn, can aid in establishing a possible link between BT, subsequent host responses and severity of liver disease.

연구 유형

관찰

등록 (실제)

30

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Institutes of Health Clinical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Primary clinical patients with chronic HCV infection divided into 2 groups according to liver fibrosis stage.

설명

  • INCLUSION CRITERIA:

    1. All age greater than 18 male or female
    2. Capacity to provide written informed consent
    3. Evidence of HCV RNA in 2 serum samples at least 6 months apart.
    4. All HCV genotypes
    5. Liver biopsy in the last 2 years prior to enrollment showing Ishak fibrosis score of either 0-1 or 5-6. An alternative to liver biopsy will be a Fibroscan study performed in the 6 months prior to study enrollment showing a score of either kPa <7 or above 13.
    6. Child-Pugh score less than or equal to 6
    7. Prior to each liver biopsy and portal vein cannulation procedure, blood will be drawn for CBC, PT/INR & acute care panel.

EXCLUSION CRITERIA:

  1. Pregnant women or females at child bearing age not taking measures to prevent pregnancy during the period of study

  2. Patients currently on treatment for hepatitis C

  3. Clinical, serologic or histopathologic evidence supporting other etiologies of chronic liver disease besides HCV

  4. Current or past clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy etc.)

  5. Cross sectional liver imaging study from the past 6 months showing a focal lesion suspicious of hepatocellular carcinoma and/or alpha-fetoprotein level greater than 200 ng/mL.

  6. Patients with active bacterial, viral or fungal, systemic or localized infection.

  7. Antibiotic treatment 30 days prior to study enrollment

  8. History of chronic inflammatory diseases of the bowel (Crohn s disease, Ulcerative colitis and celiac disease)

  9. History of congestive heart failure of moderate to severe degree.

  10. History of non-cirrhotic portal hypertension or portal vein thrombosis

  11. Patients with severe allergic reactions to iodine contrast, which cannot be controlled by premedication with antihistamines and steroids.

  12. EXCLUSION CRITERIA FOR MRI:

    12.1 Subjects with contraindication to MRI scanning. These contraindications include but are not limited to the following devices or conditions:

    <TAB>a. Implanted cardiac pacemaker or defibrillator

    <TAB>b. Cochlear Implants

    <TAB>c. Ocular foreign body (e.g. metal shavings)

    <TAB>d. Embedded shrapnel fragments

    <TAB>e. Central nervous system aneurysm clips

    <TAB>f. Implanted neural stimulator

    <TAB>g. Medical infusion pumps

    <TAB>h. Any implanted device that is incompatible with MRI.

    12.2 Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and dyspnea at rest.

    12.3 Subjects requiring sedation for MRI studies.

    12.4 Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.).

    12.5 Pregnant or lactating women.

    12.6 Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.

    12.7 For Gadolinium based and SPIO MRI Use:

    <TAB>a. History of severe allergic reaction to these contrast agents despite the use of premeditation with an anti-histaminic and cortisone.

    <TAB>b. eGFR < 60 ml/min/1.73m^2

  13. Absolute neutrophil count below 1000/mm^3, Hemoglobin level below 10.0 g/dl or platelet count lower than 70,000/mm^3.

  14. INR greater than or equal to 1.5, PTT greater than or equal to 1.3 times control and/or any known history of disease associated with increased bleeding diathesis.

  15. Serum creatinine greater than or equal to 2.0 mg/dl unless the measured creatinine clearance is greater than 60 mL/min

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: CASE_ONLY
  • 시간 관점: CROSS_SECTIONAL

코호트 및 개입

그룹/코호트
개입 / 치료
Group A

Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)

test for defining disease severity

Group B

Patients with minimal fibrosis (Ishak score 0-1).

test for defining disease severity

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Microbial product detection rate
기간: Before anti viral therapy and 9-15 months after treatment

Assess the extent of BT, explore possible mechanisms accounting for its occurrence and evaluate its effects on the immune system in different stages of liver fibrosis

Before anti viral therapy and 9-15 months after treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Dual-cholate liver function tests
기간: Baseline, and 9-15 months after treatment

Comparison of dual-cholate liver function tests and its association with microbial product levels in portal and systemic blood, between group A and group B patients.

Baseline, and 9-15 months after treatment
SPIO-MRI Kupffer cell uptake
기간: Baseline, and 9-15 months after treatment

Comparison of SPIO-MRI Kupffer cell uptake values and its association with microbial product levels in portal and systemic blood between group A and group B patients.

Baseline, and 9-15 months after treatment
Immune activation markers
기간: Baseline, and 9-15 months after treatment

Comparison of immune activation markers to bacterial products in liver tissue between group A and group B patients before and after HCV treatment.

Baseline, and 9-15 months after treatment
Pro and anti-inflammatory gene transcription
기간: Baseline, and 9-15 months after treatment

Comparison of pro and anti-inflammatory gene transcription analysis in between group A and group B patients

Baseline, and 9-15 months after treatment
Fecal microbiome
기간: Baseline, and 9-15 months after treatment

Comparison of fecal microbiome analysis between group A and group B patients

Baseline, and 9-15 months after treatment
Species homology
기간: Baseline, and 9-15 months after treatment

Evaluation of species homology between microbial DNA identified in portal and systemic blood and fecal samples by deep sequencing.

Baseline, and 9-15 months after treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Theo Heller, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2015년 5월 29일

기본 완료 (실제)

2017년 2월 24일

연구 완료 (실제)

2017년 4월 25일

연구 등록 날짜

최초 제출

2015년 3월 26일

QC 기준을 충족하는 최초 제출

2015년 3월 26일

처음 게시됨 (추정된)

2015년 3월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 6일

마지막으로 확인됨

2026년 3월 31일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다